Superior Planning, LLC’s Neurocrine Biosciences NBIX Stock Holding History

Superior Planning, LLC’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.97K	Buy	+28	New	+$4.5K	﹤0.01%	1291

Other funds holding NBIX

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Superior Planning, LLC's NBIX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 28 shares worth $3.97K. The stake represents ﹤0.01% of the portfolio and ranks #1291 among its holdings.

533 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Superior Planning, LLC held 28 shares of Neurocrine Biosciences worth $3.97K as of Q3 2026.
Neurocrine Biosciences was a new Superior Planning, LLC position in Q3 2026.
Neurocrine Biosciences made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1291 holding.
533 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.